相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
IFN and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus
Thomas Rose et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis
Qingyu Cheng et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
Michael Wang et al.
BLOOD (2013)
Autoimmune Rheumatic Diseases 3 Immunopathogenic mechanisms of systemic autoimmune disease
Marie Wahren-Herlenius et al.
LANCET (2013)
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
H. Travis Ichikawa et al.
ARTHRITIS AND RHEUMATISM (2012)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE
Matthew M. Seavey et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
Proteasome inhibitor-based therapy for antibody-mediated rejection
R. Carlin Walsh et al.
KIDNEY INTERNATIONAL (2012)
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
Makiko Hirai et al.
BLOOD (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Falk Hiepe et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Organization of immunological memory by bone marrow stroma
Koji Tokoyoda et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Sialic acid-binding Ig-like lectin I expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus
Robert Biesen et al.
ARTHRITIS AND RHEUMATISM (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Matthew J. Everly et al.
TRANSPLANTATION (2008)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
